Claims for Patent: 7,258,859

Summary for Patent: 7,258,859

Title:	Method for the treatment of multiple sclerosis
Abstract:	A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.
Inventor(s):	Martin; Roland (Bethesda, MD), McFarland; Henry (Gaithersburg, MD), Bielekova; Bibiana (Kensington, MD)
Assignee:	The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A)
Application Number:	10/607,598
Patent Claims:	1. A method for treating a subject with multiple sclerosis, comprising administering to the subject a therapeutically effective amount of daclizumab, in the absence of treatment with beta interferon, wherein the subject has failed to respond to previous treatment with beta interferon, thereby ameliorating a symptom of multiple sclerosis and treating the subject. 2. The method of claim 1, wherein daclizumab is administered intravenously. 3. The method of claim 1, wherein daclizumab is administered at a dose of about 1 to about 3 milligrams per kilogram intravenously. 4. The method of claim 1, wherein daclizumab is administered at a dose of about 1 per kilogram to about 2 milligrams per kilogram intravenously. 5. The method of claim 1, wherein daclizumab is administered biweekly. 6. The method of claim 1, wherein treatment of the subject results in a decreased number of contrast enhancing-lesions as evaluated by Magnetic Resonance Imaging. 7. The method of claim 1, wherein the subject has failed to respond to treatment with interferon-beta 1a. 8. The method of claim 1, wherein the subject has failed to respond to treatment with interferon-beta 1b. 9. The method of claim 1, wherein the subject has relapsing-remitting multiple sclerosis. 10. The method of claim 1, wherein the subject has secondary progressive multiple sclerosis. 11. The method of claim 1, wherein daclizumab is administered at least biweekly for a period of at least two months, thereby treating the subject. 12. The method of claim 11, wherein the antibody is administered at a dose of about 1 to about 3 milligrams per kilogram. 13. The method of claim 11, wherein the antibody is administered at a dose of about 1 milligram per kilogram to about 2 milligrams per kilogram. 14. The method of claim 11, wherein the subject has relapsing-remitting multiple sclerosis. 15. A method for treating a subject with multiple sclerosis, comprising selecting a subject with relapsing remitting multiple sclerosis who has been treated with interferon-beta and failed to respond to the interferon-beta treatment; administering to the subject intravenously a therapeutically effective amount of daclizumab wherein the subject is not treated with interferon-.beta., thereby ameliorating a symptom of multiple sclerosis and treating the subject. 16. The method of claim 15, wherein daclizumab is administered at least biweekly for a period of at least two months. 17. The method of claim 1, wherein daclizumab administered subcutaneously.

Details for Patent 7,258,859

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2022-06-28
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029	05/27/2016		2022-06-28
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029	05/26/2017		2022-06-28